Literature DB >> 16118380

Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.

Eric D Collins1, Herbert D Kleber, Robert A Whittington, Nicole E Heitler.   

Abstract

CONTEXT: Rapid opioid detoxification with opioid antagonist induction using general anesthesia has emerged as an expensive, potentially dangerous, unproven approach to treat opioid dependence.
OBJECTIVE: To determine how anesthesia-assisted detoxification with rapid antagonist induction for heroin dependence compared with 2 alternative detoxification and antagonist induction methods. DESIGN, SETTING, AND PATIENTS: A total of 106 treatment-seeking heroin-dependent patients, aged 21 through 50 years, were randomly assigned to 1 of 3 inpatient withdrawal treatments over 72 hours followed by 12 weeks of outpatient naltrexone maintenance with relapse prevention psychotherapy. This randomized trial was conducted between 2000 and 2003 at Columbia University Medical Center's Clinical Research Center. Outpatient treatment occurred at the Columbia University research service for substance use disorders. Patients were included if they had an American Society of Anesthesiologists physical status of I or II, were without major comorbid psychiatric illness, and were not dependent on other drugs or alcohol.
INTERVENTIONS: Anesthesia-assisted rapid opioid detoxification with naltrexone induction, buprenorphine-assisted rapid opioid detoxification with naltrexone induction, and clonidine-assisted opioid detoxification with delayed naltrexone induction. MAIN OUTCOME MEASURES: Withdrawal severity scores on objective and subjective scales; proportions of patients receiving naltrexone, completing inpatient detoxification, and retained in treatment; proportion of opioid-positive urine specimens.
RESULTS: Mean withdrawal severities were comparable across the 3 treatments. Compared with clonidine-assisted detoxification, the anesthesia- and buprenorphine-assisted detoxification interventions had significantly greater rates of naltrexone induction (94% anesthesia, 97% buprenorphine, and 21% clonidine), but the groups did not differ in rates of completion of inpatient detoxification. Treatment retention over 12 weeks was not significantly different among groups with 7 of 35 (20%) retained in the anesthesia-assisted group, 9 of 37 (24%) in the buprenorphine-assisted group, and 3 of 34 (9%) in the clonidine-assisted group. Induction with 50 mg of naltrexone significantly reduced the risk of dropping out (odds ratio, 0.28; 95% confidence interval, 0.15-0.51). There were no significant group differences in proportions of opioid-positive urine specimens. The anesthesia procedure was associated with 3 potentially life-threatening adverse events.
CONCLUSION: These data do not support the use of general anesthesia for heroin detoxification and rapid opioid antagonist induction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118380     DOI: 10.1001/jama.294.8.903

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  37 in total

1.  Problem drinking and low-dose naltrexone-assisted opioid detoxification.

Authors:  Paolo Mannelli; Kathleen Peindl; Ashwin A Patkar; Li-Tzy Wu; Haresh M Tharwani; David A Gorelick
Journal:  J Stud Alcohol Drugs       Date:  2011-05       Impact factor: 2.582

Review 2.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

3.  Advances in opioid antagonist treatment for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Li-Tzy Wu
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

Review 4.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

Review 5.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

Review 6.  Pharmacological strategies for detoxification.

Authors:  Alison M Diaper; Fergus D Law; Jan K Melichar
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

7.  Scopolamine detoxification technique for heroin dependence: a randomized trial.

Authors:  Sheng Liu; Longhui Li; Wenwen Shen; Xueyong Shen; Guodong Yang; Wenhua Zhou
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

8.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

Review 9.  Narrative review: buprenorphine for opioid-dependent patients in office practice.

Authors:  Lynn E Sullivan; David A Fiellin
Journal:  Ann Intern Med       Date:  2008-05-06       Impact factor: 25.391

10.  Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.

Authors:  Alexander Y Walley; Sara Lodi; Yijing Li; Dana Bernson; Hermik Babakhanlou-Chase; Thomas Land; Marc R Larochelle
Journal:  Addiction       Date:  2020-02-25       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.